Reviewer's report

**Title:** The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

**Version:** 3  **Date:** 10 September 2015

**Reviewer:** Hiromasa Yamamoto

**Reviewer's report:**

Although the authors described the results of the additional experiments using other EGFR-mutant and EGFR-wild type cell lines, they did not revise the manuscript itself. They should appropriately respond my comments (Major Compulsory Revisions).

**Level of interest:** An article of limited interest

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests.